Liposomal daunorubicin: Difference between revisions

Jump to navigation Jump to search
m (Protected "Liposomal daunorubicin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
 
Line 1: Line 1:
{{SI}}
{{SI}}
{{EH}}
 


==Overview==
==Overview==
Line 12: Line 12:
* [http://www.thebody.com/content/art42880.html Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)]
* [http://www.thebody.com/content/art42880.html Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)]


{{SIB}}
 


[[Category:Chemotherapeutic agents]]
[[Category:Chemotherapeutic agents]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 16:54, 9 August 2012

WikiDoc Resources for Liposomal daunorubicin

Articles

Most recent articles on Liposomal daunorubicin

Most cited articles on Liposomal daunorubicin

Review articles on Liposomal daunorubicin

Articles on Liposomal daunorubicin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Liposomal daunorubicin

Images of Liposomal daunorubicin

Photos of Liposomal daunorubicin

Podcasts & MP3s on Liposomal daunorubicin

Videos on Liposomal daunorubicin

Evidence Based Medicine

Cochrane Collaboration on Liposomal daunorubicin

Bandolier on Liposomal daunorubicin

TRIP on Liposomal daunorubicin

Clinical Trials

Ongoing Trials on Liposomal daunorubicin at Clinical Trials.gov

Trial results on Liposomal daunorubicin

Clinical Trials on Liposomal daunorubicin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Liposomal daunorubicin

NICE Guidance on Liposomal daunorubicin

NHS PRODIGY Guidance

FDA on Liposomal daunorubicin

CDC on Liposomal daunorubicin

Books

Books on Liposomal daunorubicin

News

Liposomal daunorubicin in the news

Be alerted to news on Liposomal daunorubicin

News trends on Liposomal daunorubicin

Commentary

Blogs on Liposomal daunorubicin

Definitions

Definitions of Liposomal daunorubicin

Patient Resources / Community

Patient resources on Liposomal daunorubicin

Discussion groups on Liposomal daunorubicin

Patient Handouts on Liposomal daunorubicin

Directions to Hospitals Treating Liposomal daunorubicin

Risk calculators and risk factors for Liposomal daunorubicin

Healthcare Provider Resources

Symptoms of Liposomal daunorubicin

Causes & Risk Factors for Liposomal daunorubicin

Diagnostic studies for Liposomal daunorubicin

Treatment of Liposomal daunorubicin

Continuing Medical Education (CME)

CME Programs on Liposomal daunorubicin

International

Liposomal daunorubicin en Espanol

Liposomal daunorubicin en Francais

Business

Liposomal daunorubicin in the Marketplace

Patents on Liposomal daunorubicin

Experimental / Informatics

List of terms related to Liposomal daunorubicin


Overview

Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.

Trade name: DaunoXome®

External links

Template:WH Template:WS